College Degree: B.A., University of Kansas
Medical Degree: Ph.D., University of Wisconsin
Fellowship: University of British Columbia
Research Interests:Breast cancer; mechanisms of metastasis; immune therapy; biological response modifiers
My laboratory is interested in identifying the mechanisms by which breast cancers grow and metastasize and in developing therapeutic strategies against breast cancer. Our studies show that overexpression of cyclooxygenase-2 is an indicator of aggressive disease and preclinical studies indicate that cyclooxygenase inhibitors may limit tumor growth and spread. Current studies examine mechanisms by which cyclooxygenase inhibitors enhance anti-tumor immunity. We are also investigating how cytokines and chemokines and their specific receptors modify tumor behavior. We have identified therapeutic activities for several cytokines and are developing strategies to inhibit chemokine receptors that promote tumor metastasis.
Kundu, N. and Fulton, A.M. Selective Cox-1 and Cox-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Research 62:2343-2346, 2002.
Dorsey, R., Kundu, N., Yang, Q., Tannenbaum, C.S., Sun, H., Hamilton, T.A. and Fulton, A.M. Immunotherapy with IL-10 depends on the CXC chemokines IP-10 and MIG. Cancer Research 62:2606-2610, 2002.
Kundu, N., Smyth, M., Samsel, L. and Fulton, A.M. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle in breast cancer cells. Breast Cancer Res. Treatment 76:57-64, 2002.
Ma, X., Yang, Q., Wilson, K.T., Kundu, N., Meltzer, S.J. and Fulton, A.M. Promoter methylation regulates cyclooxygenase (COX-2) expression in breast cancer. Breast Cancer Research 6:R316-321, 2004.
Selaru, F.M., Yin, J., Olaru, A., Mori, Y., Xu, Y., Epstein, S., Sato, F., Deacu, E., Wang, S., Sterian, A., Fulton, A.M., Abraham, J.M., Shibata, D., Baquet, C., Stass, S.A. and Meltzer, S.J. An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Research 64:1584-1588, 2004.
Walser, T.C. and Fulton, A.M. The role of chemokines in the biology and therapy of breast cancer. Breast Dis. 20:137-143, 2004.
Kundu, N., Walser, T.C., Ma, X. and Fulton, A.M. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol. Immunother. 54:981-987, 2005.
Hahn, T., Alvarez, I., Kobie, J.J., Ramanathauram, L., Dial, S., Fulton, A.M., Besselsen, D., Walker, E., and Akporiaye, E.T. dietary celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int. J. Cancer (in press), 2005.
Walser, T.C. and Fulton, A.M. Chemokine Receptors in Cancer in: The Chemokine Receptors (JK Harrison and N Lukacs, eds.), Humana Press, pp. 335-349, 2007.
Ma, X., Kundu, N., Rifat, S., Walser, T and Fulton, A.M. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Research, 66:2923-2927, 2006 (selected for cover and highlights).
Walser, T.C., Rifat, S., Ma, X., Kundu, N., Ward, C., Goloubeva, O., Johnson, M.G., Medina, J.C., Collins, T.L. and Fulton, A.M. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Research 66:7701-7707, 2006 (selected for highlights section).
Fulton, A.M., Ma, X., Kundu, N. Targeting Prostaglandin E EP Receptors to Inhibit Metastasis. Invited Review. Cancer Research 66:9794-9797, 2006.
Fulton, A., Miller, F.R., Weise, A. and Wei, W.-Z. Prospects of controlling breast cancer metastasis by immune interventions. Breast Disease 26:115-127, 2007.
Sinha, P., Clements, V.K., Fulton, A.M. and Ostrand-Rosenberg, S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Research 67:4507-4513, 2007.
Walser, T.C., Ma, X., Kundu, N., Dorsey, R., Goloubeva, O. and Fulton, A.M. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J. Immunotherapy 30:490-498, 2007.
Faculty members: Update your contact information and create a profile.